journal article·2020-08

Oxygen-producing catalase-based prodrug nanoparticles overcoming resistance in hypoxia-mediated chemo-photodynamic therapy

Xu Cheng, Le He, Jiaxi Xu, Qin Fang, Lu Yang, Yanbing Xue, Xin Wang, Rupei Tang

Acta Biomaterialia· Volume 112
Publisher page

Abstract

Extreme hypoxia inside solid tumors is the primary barrier against the advance of chemotherapy and photodynamic therapy (PDT). To address this problem, a hybrid nano-enzyme prodrug system was developed to alleviate hypoxia as well as simultaneously sensitize chemo-photodynamic therapy. Lactobionic acid (LA) and doxorubicin (DOX) precursor (cis-aconitic anhydride-linked doxorubicin, CAD) were pre-conjugated onto the side chain of catalase (CAT), then co-assembled with chlorin e6 (Ce6) to form LA-CAT-CAD@Ce6 nanoparticles (LCC@Ce6-NPs). LA as the active-targeting ligand increased cellular internalization, CAD as the pH-sensitive component triggered rapid drug release, Ce6 as the photosensitizer induced reactive oxygen species (ROS) generation, and CAT decomposed intracellular H2O2 to produce oxygen in situ. Oxygen production efficiently decreased the expression of hypoxia-inducible factor-1α (HIF-1α) and P-glycoprotein (P-gp), which enhanced chemotherapy efficiency. In addition, sufficient oxygen further amplified PDT-mediated cell-killing and apoptosis in hypoxic tumor. In vivo studies showed that combined chemo-photodynamic therapy by LCC@Ce6-NPs led to the most effective inhibition of tumor growth (TGI>90%), and even partially ablated tumor. Thus, this nano-enzyme prodrug platform can be a potentially effective treatment in clinical cancer therapy, and married to other therapeutic agents. STATEMENT OF SIGNIFICANCE: Hypoxia in solid tumors seriously impedes the efficacy of chemotherapy or photodynamic therapy. Herein, we designed hybrid nano-enzyme prodrug particles to improve hypoxia-mediated limitations on cancer therapy. Lactobionic acid (LA) as the hydrophilic outer layer of particles increased cellular uptake by receptor-mediated endocytosis, and cis-aconitic anhydride-linked doxorubicin (CAD) as the pH sensitive component inside particles efficiently triggered DOX and Ce6 release. More importantly, catalase (CAT) as the backbone of particles was capable of greatly relieving tumor hypoxia through catalyzing the decomposition of H2O2 in situ. Oxygen re-generation not only prevented hypoxia-mediated chemo-resistance, but also amplified PDT-induced ROS cell-killing ability. As a result, the multiple combination action of this nano-system could simultaneously sensitize chemo-photodynamic therapy, thus significantly enhancing tumor therapy.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery · Cancer, Hypoxia, and Metabolism

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (60)

Show source-provided references
1. Modulating tumor hypoxia by nanomedicine for effective cancer therapy10.1002/jcp.25859 ↗
2. Reengineering the tumor vasculature: improving drug delivery and efficacy10.1016/j.trecan.2018.02.010 ↗
3. Hypoxia and the extracellular matrix: drivers of tumor metastasis10.1038/nrc3726 ↗
4. Stromal barriers and strategies for the delivery of nanomedicine to desmoplastic tumors10.1016/j.jconrel.2015.08.017 ↗
5. The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy10.2147/HP.S93413 ↗
6. Oxygen-self-produced nanoplatform for relieving hypoxia and breaking resistance to sonodynamic treatment of pancreatic cancer10.1021/acsnano.7b08225 ↗
7. Tumor hypoxia relief overcomes multidrug resistance and immune inhibition for self-enhanced photodynamic therapy10.1016/j.cej.2019.122079 ↗
8. Hyperthermia: the optimal treatment to overcome radiation resistant hypoxia10.3390/cancers11010060 ↗
9. Azoreductase-responsive metal-organic framework-based nanodrug for enhanced cancer therapy via breaking hypoxiainduced chemoresistance10.1021/acsami.9b08115 ↗
10. Hypoxia-induced gene expression pattern in doxorubicin-resistant MCF-7 Cells
11. Light triggered oxygen-affording engines for repeated hypoxia-resistant photodynamic therapy10.1016/j.jconrel.2019.06.016 ↗
12. Aggressive man‐made red blood cells for hypoxia‐resistant photodynamic therapy
13. Fighting hypoxia to improve PDT
14. Hypoxic tumor therapy by hemoglobin-mediated drug delivery and reversal of hypoxia-induced chemoresistance10.1016/j.biomaterials.2018.08.004 ↗
15. Drug-induced co-assembly of albumin/catalase as smart nano-theranostics for deep intra-tumoral penetration, hypoxia relieve, and synergistic combination therapy, J10.1016/j.jconrel.2016.11.006 ↗
16. Targeted magnetic resonance imaging and modulation of hypoxia with multifunctional hyaluronic acid‐MnO2 nanoparticles in glioma10.1002/adhm.201900047 ↗
17. TaOx decorated perfluorocarbon nanodroplets as oxygen reservoirs to overcome tumor hypoxia and enhance cancer radiotherapy10.1016/j.biomaterials.2016.10.020 ↗
18. Cancer cell membrane-biomimetic oxygen nanocarrier for breaking hypoxia-induced chemoresistance10.1002/adfm.201703197 ↗
19. An implantable depot that can generate oxygen in situ for overcoming hypoxia-induced resistance to anticancer drugs in chemotherapy10.1021/jacs.6b01784 ↗
20. Oxygen-generating hybrid nanoparticles to enhance fluorescent/photoacoustic/ultrasound imaging guided tumor photodynamic therapy10.1016/j.biomaterials.2016.10.030 ↗
21. O2-generating MnO2 nanoparticles for enhanced photodynamic therapy of bladder cancer by ameliorating hypoxia10.7150/thno.22465 ↗
22. Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy10.1016/j.ejpb.2015.03.018 ↗
23. Activating peptides for cellular uptake via polymerization into high density brushes10.1039/C5SC03417E ↗
24. Rational design of cancer nanomedicine: nanoproperty integration and synchronization10.1002/adma.201606628 ↗
25. Stimuli responsive nanoparticles for controlled anti-cancer drug release10.2174/0929867325666180111095913 ↗
26. Nanoparticle-mediated combination chemotherapy and photodynamic therapy overcomes tumor drug resistance10.1016/j.jconrel.2009.09.004 ↗
27. Combination of chemotherapy and photodynamic therapy for cancer treatment with sonoporation effects10.1016/j.jconrel.2018.06.008 ↗
28. Stimuli-responsive self-assembly of nanoparticles10.1039/C8CS00787J ↗
29. Stimuli-responsive Nano-architecture drug-delivery systems to solid tumor micromilieu: past, present, and future perspectives10.1021/acsnano.8b06104 ↗
30. Cascade-amplifying synergistic effects of chemophotodynamic therapy using ROS-responsive polymeric nanocarriers10.7150/thno.24015 ↗
31. Synthetic glycopolypeptide micelle for targeted drug delivery to hepatic carcinoma10.3390/polym10060611 ↗
32. CD44 targeted delivery of siRNA by using HA-decorated nanotechnologies for KRAS silencing in cancer treatment10.1016/j.ijpharm.2019.02.032 ↗
33. Bioinspired multivalent peptide nanotubes for sialic acid targeting and imaging‐guided treatment of metastatic melanoma10.1002/smll.201900157 ↗
34. Transferrin receptor-targeted theranostic gold nanoparticles for photosensitizer delivery in brain tumors10.1039/C4NR04853A ↗
35. Acid-degradable lactobionic acid-modified soy protein nanogels crosslinked by ortho ester linkage for efficient antitumor in vivo10.1016/j.ejpb.2018.05.011 ↗
36. Bromelain-immobilized and lactobionic acid-modified chitosan nanoparticles for enhanced drug penetration in tumor tissues10.1016/j.ijbiomac.2018.04.076 ↗
37. Stepwise targeted drug delivery to liver cancer cells for enhanced therapeutic efficacy by galactose-grafted, ultra-pH-sensitive micelles10.1016/j.actbio.2017.01.031 ↗
38. Click and release: bioorthogonal approaches to “on-demand” activation of prodrugs10.1039/C8CS00395E ↗
39. Engineering graphene oxide with ultrasmall SPIONs and smart drug release for cancer theranostics10.1039/C8CC09185D ↗
40. pH-responsive gold nanoclusters-based nanoprobes for lung cancer targeted near-infrared fluorescence imaging and chemo-photodynamic therapy10.1016/j.actbio.2017.12.034 ↗
41. Acid-responsive PEGylated doxorubicin prodrug nanoparticles for neuropilin-1 receptor-mediated targeted drug delivery10.1016/j.colsurfb.2015.09.030 ↗
42. Total water-soluble sugars quantification in bio-oil using the phenol–sulfuric acid assay10.1016/j.jaap.2013.08.004 ↗
43. Novel biodegradable polylactide/poly (ethylene glycol) micelles prepared by direct dissolution method for controlled delivery of anticancer drugs10.1007/s11095-009-9949-4 ↗
44. A simple method for determination of serum catalase activity and revision of reference range10.1016/0009-8981(91)90067-M ↗
45. Applications of π-π stacking interactions in the design of drug-delivery systems10.1016/j.jconrel.2018.12.014 ↗
46. Nanoparticles evading the reticuloendothelial system: role of the supported bilayer10.1016/j.bbamem.2009.06.022 ↗
47. BSA-templated MnO2 nanoparticles as both peroxidase and oxidase mimics10.1039/c2an35700c ↗
48. A smart tumor-microenvironment responsive nanoprobe for highly selective and efficient combination therapy10.1039/C9QI01076A ↗
49. Catalase-loaded cisplatin-prodrug-constructed liposomes to overcome tumor hypoxia for enhanced chemo-radiotherapy of cancer10.1016/j.biomaterials.2017.05.025 ↗
50. An H2O2-responsive nanocarrier for dual-release of platinum anticancer drugs and O2: controlled release and enhanced cytotoxicity against cisplatin resistant cancer cells10.1039/C4CC03385J ↗
51. Novel injectable BRET-based in vivo imaging probe for detecting the activity of hypoxia-inducible factor regulated by the ubiquitin-proteasome system10.1038/srep34311 ↗
52. Regulatory mechanisms of hypoxia‐inducible factor 1 activity: two decades of knowledge10.1111/cas.13483 ↗
53. Hypoxia can impair doxorubicin resistance of non-small cell lung cancer cells by inhibiting MRP1 and P-gp expression and boosting the chemosensitizing effects of MRP1 and P-gp blockers10.1007/s13402-016-0285-5 ↗
54. Effect of biomimetic shear stress on intracellular uptake and cell-killing efficiency of doxorubicin in a free and liposomal formulation10.1016/j.ijpharm.2016.06.017 ↗
55. Multistage delivery of CDs-DOX/ICG-loaded liposome for highly penetration and effective chemo-photothermal combination therapy10.1080/10717544.2018.1482975 ↗
56. Rational design of IR820- and Ce6-based versatile micelle for single NIR laser–induced imaging and dual-modal phototherapy10.1002/smll.201802994 ↗
57. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity10.1124/pr.56.2.6 ↗
58. A tumor‐specific cascade amplification drug release nanoparticle for overcoming multidrug resistance in cancers10.1002/adma.201702342 ↗
59. pH-triggered chitosan nanogels via an ortho ester-based linkage for efficient chemotherapy10.1016/j.actbio.2017.05.003 ↗
60. Mediating tumor targeting efficiency of nanoparticles through design10.1021/nl900031y ↗